scispace - formally typeset
D

David F. Ransohoff

Researcher at University of North Carolina at Chapel Hill

Publications -  120
Citations -  16592

David F. Ransohoff is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Colorectal cancer & Mass screening. The author has an hindex of 52, co-authored 116 publications receiving 14749 citations. Previous affiliations of David F. Ransohoff include Case Western Reserve University & International Agency for Research on Cancer.

Papers
More filters
Journal ArticleDOI

Multitarget Stool DNA Testing for Colorectal-Cancer Screening

TL;DR: In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results.
Journal ArticleDOI

Proteogenomic characterization of human colon and rectal cancer

Bing Zhang, +64 more
- 18 Sep 2014 - 
TL;DR: Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.
Journal ArticleDOI

Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings.

TL;DR: Asymptomatic persons 50 years of age or older who have polyps in the distal colon are more likely to have advanced proximal neoplasia than are persons without distal polyps, and older age and male sex were associated with an increased risk.
Journal ArticleDOI

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma

TL;DR: A multilaboratory study to assess reproducibility, recovery, linear dynamic range and limits of detection and quantification of multiplexed, MRM-based assays, conducted by NCI-CPTAC demonstrates that these assays can be highly reproducible within and across laboratories and instrument platforms.
Journal ArticleDOI

Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.

TL;DR: Although the majority of neoplastic lesions identified by colonoscopy were not detected by either noninvasive test, the multitarget analysis of fecal DNA detected a greater proportion of important colorectal neoplasia than did Hemoccult II without compromising specificity.